Form 4: Sight Sciences Director Donald Zurbay Receives Significant RSU Grant Valued at $130,000

Sight Sciences, Inc. Director Donald Zurbay was granted 30,952 restricted stock units (RSUs) valued at approximately $130,000 as part of the company's non-employee director compensation program.

Summary

• Donald Zurbay, a Director at Sight Sciences, Inc. (SGHT), received a grant of 30,952 restricted stock units (RSUs) on June 5, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The total value of the RSU grant is approximately $130,000, determined by the closing price of the common stock on the grant date.
• The RSUs are scheduled to vest on the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent upon Mr. Zurbay's continued service as a director.
• Following this transaction, Mr. Zurbay beneficially owns 165,352 shares, which includes 44,400 shares of Common Stock, the 30,952 newly granted RSUs, and 90,000 shares acquirable through stock options exercisable within 60 days of June 5, 2025.

Sentiment

Score: 7

Explanation: The RSU grant is a positive event as it aligns the director's interests with shareholders and is a standard form of compensation, indicating stability in governance and compensation practices.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Donald Zurbay aligns his interests with those of the shareholders, as his compensation is tied to the company's stock performance.
• This RSU grant is part of the Issuer's Non-Employee Director Compensation Program, indicating a structured approach to executive and director incentives.

Future Outlook

The granted RSUs are forward-looking compensation, designed to vest on the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent on the director's continued service.

Management Comments

• The RSU grant reflects a component of the Issuer's Non-Employee Director Compensation Program.

Industry Context

The grant of Restricted Stock Units (RSUs) to non-employee directors is a common practice across industries, particularly in publicly traded companies, to attract and retain qualified board members and align their long-term interests with those of shareholders.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of non-employee director compensation is a standard practice widely adopted by public companies across various sectors, including medical technology and healthcare, similar to companies like Alcon Inc. or Bausch + Lomb Corporation, which also utilize equity-based incentives for their board members.
• The vesting schedule tied to continued service and a specific future date or annual meeting is also a common structure for such grants, ensuring long-term commitment from directors.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the company's stock performance, potentially leading to more shareholder-centric decision-making.
• Employees: While not directly impacted, a stable and incentivized board can contribute to overall company stability and strategic direction, indirectly benefiting employees.

Next Steps

• The RSUs are expected to vest on the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, subject to Donald Zurbay's continued service as a director.

Key Dates

Keywords

Sight Sciences, SGHT, Form 4, insider transaction, restricted stock units, RSU grant, director compensation, equity compensation, beneficial ownership